105 related articles for article (PubMed ID: 3672559)
1. Oral kinetics and bioavailability of the cholinesterase reactivator HI-6 after administration of 2 different formulations of tablets to dogs.
Maksimović M; Jovanović D; Kovacević V; Bokonjić D
Toxicol Lett; 1987 Nov; 39(1):85-91. PubMed ID: 3672559
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability and disposition kinetics of HI-6 in Beagle dogs.
Baggot JD; Buckpitt A; Johnson D; Brennan P; Chung H
Biopharm Drug Dispos; 1993 Mar; 14(2):93-105. PubMed ID: 8453028
[TBL] [Abstract][Full Text] [Related]
3. Intravenous application of HI-6 salts (dichloride and dimethansulphonate) in pigs: comparison with pharmacokinetics profile after intramuscular administration.
Zdarova Karasova J; Zemek F; Kunes M; Kvetina J; Chladek J; Jun D; Bures J; Tachecí I; Kuca K
Neuro Endocrinol Lett; 2013; 34 Suppl 2():74-8. PubMed ID: 24362096
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the oxime HI-6 from a mixture with atropine sulphate in dogs.
Jovanović D; Kovacević V; Maksimović M
Pharmacol Toxicol; 1992 Nov; 71(5):340-2. PubMed ID: 1448446
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors.
Spöhrer U; Thiermann H; Klimmek R; Eyer P
Arch Toxicol; 1994; 68(8):480-9. PubMed ID: 7802588
[TBL] [Abstract][Full Text] [Related]
6. Oral forms of the oxime HI-6: a study of pharmacokinetics and tolerance after administration to healthy volunteers.
Jovanovic D; Maksimovic M; Joksovic D; Kovacevic V
Vet Hum Toxicol; 1990 Oct; 32(5):419-21. PubMed ID: 2238436
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs.
Karasova JZ; Kvetina J; Tacheci I; Radochova V; Musilek K; Kuca K; Bures J
Toxicol Lett; 2017 May; 273():20-25. PubMed ID: 28343895
[TBL] [Abstract][Full Text] [Related]
8. The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine.
Clement JG; Bailey DG; Madill HD; Tran LT; Spence JD
Biopharm Drug Dispos; 1995 Jul; 16(5):415-25. PubMed ID: 8527690
[TBL] [Abstract][Full Text] [Related]
9. Trimedoxime and HI-6: kinetic comparison after intravenous administration to mice.
Milic B; Maksimovic M; Nedelijkovic M
Pharmacol Toxicol; 1996 Apr; 78(4):269-72. PubMed ID: 8861786
[TBL] [Abstract][Full Text] [Related]
10. HI-6 pharmacokinetics in rabbits after intravenous and intramuscular administration.
Lukey BJ; Woodard CL; Clark CR; McCluskey MP
J Pharm Pharmacol; 1992 Aug; 44(8):690-2. PubMed ID: 1359099
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7.
Thiermann H; Radtke M; Spöhrer U; Klimmek R; Eyer P
Arch Toxicol; 1996; 70(5):293-9. PubMed ID: 8852700
[TBL] [Abstract][Full Text] [Related]
12. HI-6 oxime (an acetylcholinesterase reactivator): blood plasma pharmacokinetics and organ distribution in experimental pigs.
Kuneš M; Květina J; Bureš J; Karasová JZ; Pavlík M; Tachecí I; Musílek K; Kuca K
Neuro Endocrinol Lett; 2014; 35 Suppl 2():191-6. PubMed ID: 25638385
[TBL] [Abstract][Full Text] [Related]
13. HI-6 and 2-PAM in sheep: pharmacokinetics and effects on muscle tissue following intramuscular injection.
Moore DH; Hayward IJ; Tucker FS; Lukey B
Biopharm Drug Dispos; 1991 Apr; 12(3):223-32. PubMed ID: 2059672
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of the oxime, HI-6, in patients with acute organophosphorus insecticide poisoning].
Jovanović D; Randelović S; Joksović D; Todorović V
Vojnosanit Pregl; 1993; 50(1):27-31. PubMed ID: 8493783
[TBL] [Abstract][Full Text] [Related]
15. Disposition of HI-6 oxime in rats after intravenous and intramuscular administration.
Simons KJ; Briggs CJ
J Pharm Pharmacol; 1985 May; 37(5):367-9. PubMed ID: 2862253
[TBL] [Abstract][Full Text] [Related]
16. Effect of poisoning by soman (pinacolyl methylphosphonofluoridate) on the serum half-life of the cholinesterase reactivator HI-6 in mice.
Clement JG; Simons KJ; Briggs CJ
Biopharm Drug Dispos; 1988; 9(2):177-86. PubMed ID: 3370306
[TBL] [Abstract][Full Text] [Related]
17. Asoxime (HI-6) impact on dogs after one and tenfold therapeutic doses: assessment of adverse effects, distribution, and oxidative stress.
Pohanka M; Novotny L; Zdarova-Karasova J; Bandouchova H; Zemek F; Hrabinova M; Misik J; Kuca K; Bajgar J; Zitka O; Cernei N; Kizek R; Pikula J
Environ Toxicol Pharmacol; 2011 Jul; 32(1):75-81. PubMed ID: 21787733
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia.
Clement JG; Lee MJ; Simons KJ; Briggs CJ
Biopharm Drug Dispos; 1990 Apr; 11(3):227-32. PubMed ID: 2328309
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of two acetylcholinesterase reactivators, trimedoxime and newly synthesized oxime K027, in rat plasma.
Karasova JZ; Chladek J; Hroch M; Josef F; Hnidkova D; Kuca K
J Appl Toxicol; 2013 Jan; 33(1):18-23. PubMed ID: 21717485
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of nerve agent-inhibited human acetylcholinesterase by obidoxime, HI-6 and obidoxime+HI-6: Kinetic in vitro study with simulated nerve agent toxicokinetics and oxime pharmacokinetics.
Worek F; Koller M; Thiermann H; Wille T
Toxicology; 2016 Mar; 350-352():25-30. PubMed ID: 27153754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
